Anticonvulsant Potiga Lowers Motor Neuron Excitability in ALS Patients, Phase 2 Trial Shows

Anticonvulsant Potiga Lowers Motor Neuron Excitability in ALS Patients, Phase 2 Trial Shows

Treatment with the anticonvulsant Potiga (ezogabine) lessened abnormal motor neuron excitability, or responsiveness, in patients with amyotrophic lateral sclerosis (ALS), according to top-line results of a Phase 2 clinical trial. Findings were presented at the recent 29th International Symposium on ALS/ Motor Neurone Disease in Glasgow, Scotland, by Brian…

The ALS Game Board of Life

I’ve always looked forward to December; it’s a month filled with decorations, holiday gifts, and happy social gatherings. But this month eight years ago, I was diagnosed with ALS, so December now marks a sad point in my life as well. Like so many who live with…